Fwd: Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, May 22, 2008 at 5:14 PM
Subject: Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy.
To: mesothelioma77@gmail.com


[1]AJR Am J Roentgenol. 2008 Jun; 190(6): 1630-6
Hattangadi J, Park C, Rembert J, Klifa C, Hwang J, Gibbs J, Hylton N

OBJECTIVE: Cancerous neovascular changes in histologically normal-appearing breast tissue have been shown to increase risk for local recurrence after breast-conserving therapy. However, the imaging characteristics of this tissue have not been well studied. We hypothesized that signal enhancement ratios from dynamic contrast-enhanced breast MRI could be used to analyze the contrast kinetics of microvasculature in breast stroma beyond the tumor margin and that this information can be developed to improve local treatment options. MATERIALS AND METHODS: Signal enhancement ratio analysis of nontumor breast stroma was performed on dynamic contrast-enhanced MRI scans of 42 patients who received neoadjuvant chemotherapy for invasive breast cancer performed before chemotherapy (scan 1) and after one cycle of chemotherapy (scan 2). Stromal signal enhancement ratio values were then correlated to several clinical parameters and to clinical outcome using univariate and multivariate analyses. Median follow-up for the group was 52.1 months. RESULTS: On univariate analysis, factors that were significantly associated (p

___
Source: http://www.hubmed.org/display.cgi?uids=18492917
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, May 21, 2008 at 8:29 AM
Subject: Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.
To: mesothelioma77@gmail.com


[1]J Pathol. 2008 Apr 14;
Chen D, Chu CY, Chen CY, Yang HC, Chiang YY, Lin TY, Chiang IP, Chuang DY, Yu CC, Chow KC

Oncostatin M (OSM) is a member of the interleukin-6 (IL-6) family of cytokines, and binds to the OSM receptor (OSMR) to inhibit cancer growth. Four forms of OSMR have been identified: leukemia inhibitory factor receptor (LIFR), OSMRbeta, short-form OSMR (OSMRs) and soluble OSMR (sOSMR). In this study, we examined the type and expression of OSMR in lung adenocarcinomas (LADCs). Expression of OSMR was determined by reverse transcription-polymerase chain reaction (RT-PCR), immunoblotting, immunohistochemistry and confocal immunofluorescent microscopy (CIM). Our results showed that, among the four forms of OSMR, OSMRs was mainly expressed in LADC, and expression level of OSMRs correlated with patient survival. CIM revealed that OSMRs was localized on the cell membrane of LADC cell lines in vitro. OSMRs acts as a decoy receptor by reducing the inhibitory effect of OSM on cell growth. Decrease in OSMRs expression by siRNA increased cell sensitivity to OSM, and ectopic expression of OSMRs reduced cell sensitivity to OSM. These results suggest that expression of OSMRs, which operates as a decoy receptor for OSM, is correlated with disease progression and adverse prognosis in patients with LADC. Copyright (c) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.



___
Source: http://www.hubmed.org/display.cgi?uids=18491353
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc